EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Conditional in vivo deletion of LYN kinase has little effect on a BRCA1 loss-of-function-associated mammary tumour model

Giusy Tornillo, Lauren Warrington, Howard Kendrick iD, Adam T Higgins, Trevor Hay iD, Sam Beck, Matthew J Smalley iD

Disease Models & Mechanisms · 2024

DOI: 10.1242/dmm.050211 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Disease Models & Mechanisms, 2024. Verfasst von Giusy Tornillo und 6 weiteren Autor:innen. Beteiligte Einrichtung: The European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Cardiff CF24 4HQ, UK. Hauptthemen laut MEDLINE: Breast Neoplasms, Mammary Neoplasms, Animal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Breast Cancer Now, Breast Cancer Research Aid, Cardiff University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

LYN kinase is expressed in BRCA1 loss-of-function-dependent mouse mammary tumours, in the cells of origin of such tumours, and in human breast cancer. Suppressing LYN kinase activity in BRCA1-defective cell lines as well as in in vitro cultures of Brca1-null mouse mammary tumours is deleterious to their growth. Here, we examined the interaction between LYN kinase and BRCA1 loss-of-function in an in vivo mouse mammary tumour model, using conditional knockout Brca1 and Lyn alleles. Comparison of Brca1 tumour cohorts showed little difference in mammary tumour formation between animals that were wild type, heterozygous or homozygous for the conditional Lyn allele, although this was confounded by factors including incomplete Lyn recombination in some tumours. RNA-sequencing analysis demonstrated that tumours with high levels of Lyn gene expression had a slower doubling time, but this was not correlated with levels of LYN staining in tumour cells themselves. Rather, high Lyn expression and slower tumour growth were likely a result of B-cell infiltration. The multifaceted role of LYN indicates that it is likely to present difficulties as a therapeutic target in breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsMammary Neoplasms, AnimalAnimalsFemaleHumansMiceBRCA1 ProteinBreastCell LineMice, Knockoutsrc-Family Kinases

Stichwörter der Autor:innen

BRCA1Cre-LoxPLYN kinase

Substanzen

BRCA1 ProteinBRCA1 protein, humanlyn protein-tyrosine kinasesrc-Family KinasesBrca1 protein, mouse

Autor:innen und Institutionen

  • The European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Cardiff CF24 4HQ, UK.
  • Independent Anatomic Pathology Ltd, Calyx House, South Road, Taunton TA1 3DU, UK.

ORCID-Profile: Howard Kendrick, Trevor Hay, Matthew J Smalley

Förderung

  • Breast Cancer Now
  • Breast Cancer Research Aid
  • Cardiff University

Zitieren

APA

Tornillo, G., Warrington, L., Kendrick, H., Higgins, A. T., Hay, T., Beck, S., & Smalley, M. J. (2024). Conditional in vivo deletion of LYN kinase has little effect on a BRCA1 loss-of-function-associated mammary tumour model. Disease Models & Mechanisms. https://doi.org/10.1242/dmm.050211

Vancouver

Tornillo G, Warrington L, Kendrick H, Higgins AT, Hay T, Beck S, et al. Conditional in vivo deletion of LYN kinase has little effect on a BRCA1 loss-of-function-associated mammary tumour model. Disease Models & Mechanisms. 2024. doi:10.1242/dmm.050211

BibTeX
@article{Tornillo2024,
  author = {Tornillo, Giusy and Warrington, Lauren and Kendrick, Howard and Higgins, Adam T and Hay, Trevor and Beck, Sam and Smalley, Matthew J},
  title = {Conditional in vivo deletion of LYN kinase has little effect on a BRCA1 loss-of-function-associated mammary tumour model},
  journal = {Disease Models & Mechanisms},
  year = {2024},
  doi = {10.1242/dmm.050211}
}
Kostenlos starten →